Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 14/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.39 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.35 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24950362 | 0.92 | CA12 (0.44) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL23918314 | 0.87 | CA12 (0.43) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL23634911 | 0.87 | CA12 (0.43) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL23918313 | 0.87 | CA12 (0.43) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL24939662 | 0.86 | CRBN (0.43) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL24938770 | 0.84 | DDB1 (0.44) | DDB1CRBNBRD4CREBBPGSPT1 | |
| SCHEMBL29322819 | 0.83 | DDB1 (0.50) | DDB1CRBN | |
| SCHEMBL24754295 | 0.82 | DDB1 (0.48) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL27064809 | 0.79 | DDB1 (0.44) | CA12CA1CA9DDB1CRBN | |
| SCHEMBL26158805 | 0.79 | CRBN (0.47) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4400499-A1 | GLUTARIMIDE COMPOUND AND USE THEREOF | Medshine Discovery Inc. (CN) | 2024-07-17 | — | — | EP | disclosed |
| EP-4310083-A1 | FURAN FUSED RING-SUBSTITUTED GLUTARIMIDE COMPOUND | Medshine Discovery Inc. (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | MEDSHINE DISCOVERY INC. (CN) | 2023-05-25 | — | — | US | disclosed |
| WO-2023001028-A1 | HETEROARYL-3-PIPERIDINEDIONE COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2023-01-26 | — | — | WO | disclosed |
| EP-4122925-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | Medshine Discovery Inc. (CN) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158152-A1 | PROTEOLYSIS REGULATOR AND METHOD FOR USING SAME | PSMA6, PSMC1, PSMA1 | CA12 2596/4885CA1 1349/4885CA9 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.